CareDx (CDNA) Cash & Equivalents (2013 - 2026)

CareDx has disclosed Cash & Equivalents across 14 years of filings, most recently posting $77.9 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $77.9 million, down 12.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.9 million (down 12.19% YoY), and the FY2025 annual result was $65.4 million, down 42.95% from the prior year.
• Cash & Equivalents came in at $77.9 million for Q1 2026 at CareDx, up from $65.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $171.9 million in Q1 2022 to a low of $65.4 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $88.7 million (2025), against an average of $95.5 million.
• Across the five-year window, Cash & Equivalents tumbled 76.5% in 2022 and surged 39.53% in 2024, its largest moves.
• CareDx's Cash & Equivalents stood at $89.9 million in 2022, then dropped by 8.59% to $82.2 million in 2023, then soared by 39.53% to $114.7 million in 2024, then tumbled by 42.95% to $65.4 million in 2025, then gained by 19.1% to $77.9 million in 2026.
• The last three Cash & Equivalents figures came in at $77.9 million (Q1 2026), $65.4 million (Q4 2025), and $91.4 million (Q3 2025), per Business Quant data.